Question explored with the scientific record
what data do you have on the lipids used for the saRNA vaccine Kostaive?
The short version: the publicly available evidence does not disclose the specific lipid composition of Kostaive.
The evidence retrieved contains no study that names Kostaive’s lipid nanoparticle formulation. The closest data come from general saRNA LNP research: one study uses SM102-based LNPs with a 50:10:38.5:1.5 molar ratio (ionizable lipid:DSPC:cholesterol:DMG-PEG) and reports >90% encapsulation efficiency and ~80 nm particle size [3]. Another uses ALC-0315 LNPs with the same molar ratio but DOPE instead of DSPC [5]. A third reviews the standard LNP composition range as 35–50% ionizable lipid, 10–15% phospholipid, 25–40% cholesterol, and 1–3% PEG-lipid [6]. None of these is Kostaive.
The manufacturer has not published Kostaive’s lipid identities, ratios, or preclinical safety data in the studies retrieved. Without that information, you cannot assess the colloidal stability of the particles, the zeta potential of the formulation, or the long-term biodistribution of the lipids. The burden of proof is on the manufacturer, and they have not met it in the public record.
My call: the evidence retrieved does not answer the question. Confidence: not clear — the gap itself is the finding.
Sources used 24
-
Laminar fluid ejection device enables high yield and preservation of mRNA and SaRNA LNP formulations
This study evaluates the impact of three different intranasal delivery systems on the stability, recovery, and functionality of lipid nanoparticles (LNPs) encapsulating mRNA and self-amplifying RNA (saRNA), demonstrating that the Laminar Fluid Ejection (LFE) Device significantly…
DOI: 10.1038/s41598-025-03309-9 -
Single injection of modified self-amplifying RNA encoding a CD19 bispecific T cell engager mediates long-term malignant B cell clearance
Single intravenous injection of a 5-methylcytidine–modified self-amplifying RNA encoding a CD19 x CD3 BiTE, formulated in lipid nanoparticles, yields durable BiTE expression in vivo and achieves long-term clearance of malignant B cells, outperforming mRNA-BiTE and Blinatumomab p…
DOI: 10.64898/2026.04.18.719371 -
Impact of B18R-Encoding Messenger Ribonucleic Acid Co-Delivery on Neutralizing Antibody Production in Self-Amplifying Messenger Ribonucleic Acid Vaccines
The study demonstrates that co-delivery of B18R-encoding mRNA with a optimized, purified self-amplifying mRNA (saRNA) vaccine formulated in SM102-based lipid nanoparticles yields sustained antigen expression and substantially higher neutralizing antibody responses in mice than a…
DOI: 10.3390/vaccines13050537 -
Specialization of ubiquitin ligases to distinct nucleic acid sensors
Using a large-scale AlphaFold-based screening pipeline, this study reveals that SPRY-domain-containing ubiquitin ligases encode substrate specificity for nucleic acid sensors (e.g., RIG-I, ZAP, OAS1) and demonstrates conservation and divergence of TRIM25 and Riplet across verteb…
DOI: 10.1101/2025.10.01.678329 -
Modified self-amplifying RNA mediates robust and prolonged gene expression in the mammalian brain
Modified self-amplifying RNA encoding fluorescent proteins, delivered by ALC-0315 lipid nanoparticles with hm5C modification, yields robust and prolonged gene expression in the mammalian brain, predominantly transfecting astrocytes at the injection site with notable retrograde l…
DOI: 10.1101/2025.10.30.685635 -
mRNA therapeutics beyond vaccines: dosing precision challenges and clinical translation framework
A comprehensive review of dosing precision challenges in mRNA therapeutics beyond vaccines, analyzing amplification kinetics, delivery system limitations, regulatory considerations, and a framework for selecting clinical applications based on tolerance for protein expression var…
DOI: 10.1039/d5pm00159e -
Advancing Lung Cancer Treatment: mRNA Therapeutics and Delivery Strategies
This Mini-Review surveys advances in delivering mRNA-based therapeutics to the lung for cancer, detailing pulmonary delivery barriers, design strategies to enhance stability and endosomal escape, lung-targeting carriers (lipid nanoparticles and extracellular vesicle–mimetics), a…
DOI: 10.1021/acs.nanolett.5c03826 -
Nucleic acid drugs: recent progress and future perspectives
A comprehensive review of nucleic acid drugs (NADs), their classifications (ASOs, siRNAs, miRNAs, saRNAs, mRNA, CRISPR/Cas), delivery strategies (LNPs, GalNAc, exosomes, peptides, polymers), clinical progress, delivery challenges, and future perspectives for broadening NADs’ the…
DOI: 10.1038/s41392-024-02035-4 -
Self-amplifying RNA vaccines for infectious diseases
A comprehensive review of self-amplifying RNA (saRNA) vaccine technology for infectious diseases, covering production, delivery platforms, immune-modulation, preclinical and early clinical progress across multiple pathogens, and the potential for rapid, cell-free manufacturing a…
DOI: 10.1038/s41434-020-00204-y -
The evaluation of novel oral vaccines based on self-amplifying RNA lipid nanparticles (saRNA LNPs), saRNA transfected Lactobacillus plantarum LNPs, and saRNA transfected Lactobacillus plantarum to neutralize SARS-CoV-2 variants alpha and delta
This study evaluates novel oral vaccines based on self-amplifying RNA lipid nanoparticles and Lactobacillus plantarum to neutralize SARS-CoV-2 variants alpha and delta, demonstrating significant immune responses in mice.
DOI: 10.1038/s41598-021-00830-5 -
Advancements in mRNA Vaccine Technology: A Review of Applications in Infectious Disease Prevention
mRNA vaccine technology enables rapid design and delivery of vaccines using lipid nanoparticles, with COVID-19 vaccines achieving high efficacy and real-world impact, while expanding research toward other infectious diseases and cancer, and facing cold-chain, regulatory, and equ…
DOI: 10.70389/pjid.100004 -
Moderna COVID-19 Vaccine: Mechanisms, Efficacy, Safety, and Future Directions
A comprehensive review of Moderna's mRNA-1273 vaccine, detailing its lipid nanoparticle delivery mechanism, clinical efficacy (notably Phase III COVE results), safety profile, durability of immunity, variant challenges, and future directions for mRNA vaccines.
DOI: 10.56028/aetr.14.1.1525.2025 -
Biotechnology and the Future of Vaccines—From Novel Routes and Vectors to Safety, Efficacy, and Global Impact
An editorial synthesis of six Vaccines special‑issue articles showing how biotechnology—lipid nanoparticles, polymeric micelles, bacterial vectors, and novel administration routes—is transforming vaccine design, delivery, safety assessment, and global impact while outlining ongo…
DOI: 10.3390/vaccines13101043 -
Lipid Nanoparticle Development for A Fluvid mRNA Vaccine Targeting Seasonal Influenza and SARS-CoV-2
This study developed a bivalent mRNA vaccine encapsulated in lipid nanoparticles targeting both seasonal influenza and SARS-CoV-2, demonstrating robust immune responses and 100% protective efficacy in mouse models.
DOI: 10.1038/s41541-025-01153-6 -
Artificial Intelligence-Driven Strategies for Targeted Delivery and Enhanced Stability of RNA-Based Lipid Nanoparticle Cancer Vaccines
A comprehensive, AI-driven overview of how machine learning, generative models, and digital-twin/regulatory frameworks are advancing the stability and tumor-targeted delivery of RNA-based lipid nanoparticle (LNP) cancer vaccines, highlighting virtual lipid screening, novel lipid…
DOI: 10.3390/pharmaceutics17080992 -
Comparative Analysis of Lipid Nanoparticles in Pfizer-BioNTech and Moderna COVID-19 Vaccines: Insights from Molecular Dynamics Simulations
This study employs molecular dynamics simulations to compare the structural and stability differences of lipid nanoparticles in the Pfizer-BioNTech and Moderna COVID-19 vaccines, revealing that the ionizable lipid tail of BNT162b exhibits a higher degree of branching than that o…
DOI: 10.1101/2024.10.04.616619 -
Delivery of mRNA Vaccine and its Application for COVID-19
A concise review of mRNA vaccine delivery strategies with emphasis on lipid nanoparticles (LNPs) for COVID-19, comparing naked mRNA, dendritic-cell–based, polymer-based, cationic nanoemulsions, and peptide-based delivery, and summarizing the clinical use of BNT162b2 and mRNA-127…
DOI: 10.54097/tqqk4h91 -
Impact of lipid nanoparticle size on mRNA vaccine immunogenicity
The study systematically isolates and assesses how lipid nanoparticle (LNP) size from 60 to 200 nm, while keeping lipid composition constant, impacts mRNA CMV vaccine immunogenicity in mice and non-human primates, finding a strong size-dependence in mice with an apparent optimal…
DOI: 10.1016/j.jconrel.2021.05.021 -
Multicomponent thiolactone-based ionizable lipid screening platform for efficient and tunable mRNA delivery to the lungs
A high-throughput STAAR platform for rapid synthesis and in vivo screening of 91 thiolactone-based ionizable lipids identifies CP-LC-0729 with superior lung-targeted mRNA delivery and demonstrates a permanently cationic lipid that yields a 32-fold increase in lung protein expres…
DOI: 10.1038/s42004-025-01516-z -
Effect of lipid structural modifications on their intermolecular hydrogen bonding interactions and membrane functions
Intermolecular hydrogen bonding among lipids influences phase transition temperatures, hexagonal phase formation, and protein-lipid interactions, providing a regulatory mechanism for membrane functions.
DOI: 10.1139/o86-008 -
Transport of alkali cations through thin lipid membranes by (222)C10-Cryptand, an ionizable mobile carrier
This study investigates the transport kinetics of K+ and Na+ ions through lipid membranes using (222)C10-cryptand and valinomycin, revealing differences in affinity and transport efficiency influenced by pH and carrier concentration.
DOI: 10.1007/bf01870668 -
Transmembrane Complexes of DAP12 Crystallized in Lipid Membranes Provide Insights into Control of Oligomerization in Immunoreceptor Assembly
This study reveals, in lipid membranes, that the DAP12 transmembrane domain forms trimeric and tetrameric assemblies coordinated by polar residues and bound cations, and that these oligomers compete with receptor assembly in the ER; the findings are supported by lipid-cubic-phas…
DOI: 10.1016/j.celrep.2015.04.045 -
Modulation by subphase pH and ions, of 12-(9-anthroyloxy)stearic acid mobility in phospholipid monolayers. A fluorescence recovery after photobleaching study
The study uses fluorescence recovery after photobleaching (FRAP) of the 12-(9-anthroyloxy)stearic acid probe in phospholipid monolayers to show that the lateral mobility of acidic phospholipids in the liquid-expanded state is modulated by the chemical nature and concentration of…
DOI: 10.1016/0009-3084(88)90052-7 -
Polymer-induced leakage of cations from dioleoyl phosphatidylcholine and phosphatidylglycerol liposomes
A pH-responsive polyacid (PEAA) binds to DOPC and DOPG liposomes and induces Ca2+ and Na+ leakage through transient pores, with leakage rates modulated by pH, ionic strength, polymer concentration, and lipid charge.
DOI: 10.1016/s0168-3659(00)00209-1